Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia.
OBJECTIVE
To evaluate the treatment of simple endometrial hyperplasia without atypia with different gestagens.


METHODS
Sixty premenopausal women with histologically documented endometrial hyperplasia without atypia were included in this prospective controlled study. Patients were randomized into two groups: Group I included 30 patients who received lynestrenol (LYN) in a dose of 15 mg/d, while Group II included 30 patients who received micronized progesterone (MP) 200 mg/d for 12 days per cycle for 3 months. Patients were reevaluated with endometrial curettage after treatment. MP and LYN regimens were compared to regression, resolution or persistence rates and metabolic parameters.


RESULTS
After 3 months of treatment in both groups, none of the cases progressed. In LYN group, the rate of resolution was observed to be higher compared to MP group (p = 0.045). LYN was found more effective inducing resolution in patients more than 45 years compared to MP (p = 0.036). When we compare both groups after 3 months of treatment, there was no statistically significant difference in BMI, total cholesterol, HDL, LDL and fibrinogen level between two groups. The rate of patients without any side effects was found to be similar in both groups (p = 0.5).


CONCLUSIONS
LYN which is a synthetic progestin ensures better endometrial control compared to MP in simple hyperplasia without atypia in the patients of premenopausal age especially in ages more than 45 years.
Department of Obstetrics and Gynecology, Etlik Zübeyde Hanim Womens Health Research Hospital, Guvenlik Caddesi, 21/5, Aşagı Ayrancı, 06010, Ankara, Turkey, yytasci@yahoo.com.
Yasemin
Y
Tasci
Oznur Gokcag
OG
Polat
Serdinc
S
Ozdogan
Deniz
D
Karcaaltincaba
Levent
L
Seckin
Salim
S
Erkaya
D000328:Adult; D015992:Body Mass Index; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage*; D003475:Curettage; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008234:Lynestrenol / Q000008:administration & dosage*; D008875:Middle Aged; D017697:Premenopause; D011374:Progesterone / Q000008:administration & dosage*; D011372:Progestins / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome
D003280:Contraceptives, Oral, Synthetic; D011372:Progestins; D011374:Progesterone; D008234:Lynestrenol